Where it comes from
- Made in
- The NPY/AgRP neurons of the arcuate nucleus, and the adrenal
- Sent out by
- Fasting and ghrelin switch the neurons on; leptin, insulin and PYY switch them off
- Acts on
- MC4R neurons of the paraventricular nucleus
- Other melanocortin targets
What it does
In medicine
- No medicine copies it or blocks it. Blood AgRP rises with fasting and is a research marker
- Setmelanotide works below the level at which AgRP acts: it activates MC4R directly, so the blockade AgRP imposes does not stand in its way. It is approved for obesity caused by faults in the melanocortin pathway 3
Beyond the body’s own use
- AgRP is studied in anorexia nervosa and in cachexia, conditions in which appetite is lost, and from the other direction in obesity; no AgRP preparation or blocker has been given to a person 1
- Nothing containing AgRP is approved or obtainable outside the laboratory
- The clearest evidence of how much it matters comes from its neurons rather than the peptide: silencing the AgRP neurons of an adult mouse stops it eating altogether, while the same neurons can be removed in a newborn with little effect 2
Sources
- Ollmann et al., Antagonism of central melanocortin receptors by agouti-related protein, Science 1997
- Luquet et al., NPY/AgRP neurons are essential for feeding in adult mice, Science 2005
- Clément et al., Efficacy and safety of setmelanotide in severe obesity due to LEPR or POMC deficiency, Lancet Diabetes and Endocrinology 2020
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.